With US drug pricing under pressure from a new Medicare price negotiation program being implemented under the Inflation Reduction Act (IRA), some of industry’s top leaders said they were doubtful the US would ever move toward true value-based pricing.
Pfizer Inc. CEO Albert Bourla, Eli Lilly and Company CEO David Ricks and Seagen Inc. CEO David...